Dupixent and Narrowband UVB for Atopic Dermatitis

Last updated: March 14, 2024
Sponsor: Psoriasis Treatment Center of Central New Jersey
Overall Status: Active - Recruiting

Phase

4

Condition

Dermatitis, Atopic

Eczema (Atopic Dermatitis - Pediatric)

Rosacea

Treatment

Dupixent

Clinical Study ID

NCT05285839
ETC01
  • Ages > 18
  • All Genders

Study Summary

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female adult ≥ 18 years of age;
  • Diagnosis of moderate to severe atopic dermatitis as defined at baseline by:
  • EASI score of 16 or greater,
  • IGA score of 3 or greater
  • BSA of 10% or greater,

Exclusion

Exclusion Criteria:

  • Subjects with previous exposure to dupilumab.
  • Known or suspected hypersensitivity to dupilumab or any of its excipients.
  • History of photosensitivity.

Study Design

Total Participants: 40
Treatment Group(s): 1
Primary Treatment: Dupixent
Phase: 4
Study Start date:
April 19, 2022
Estimated Completion Date:
December 15, 2024

Study Description

24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.

Connect with a study center

  • Eczema Treatment Center of New Jersey

    East Windsor, New Jersey 08520
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.